A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.
Orgenesis's net issuance of preferred for the
three
months ended in Dec. 2021 was $0.00 Mil. The number is
0, which means that Orgenesis has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.
Orgenesis's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2021 was $0.00 Mil.
Orgenesis Net Issuance of Preferred Stock Historical Data
The historical data trend for Orgenesis's Net Issuance of Preferred Stock can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Net Issuance of Preferred Stock
-
-
-
-
-
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Net Issuance of Preferred Stock
-
-
-
-
-
Orgenesis Net Issuance of Preferred Stock Calculation
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis Net Issuance of Preferred Stock Related Terms
Thank you for viewing the detailed overview of Orgenesis's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.03(1.45%) Volume: 4,898 9:50AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
